Advanced Oncotherapy (FRA:R3I1) Total Current Assets : €38.19 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Advanced Oncotherapy's total current assets for the quarter that ended in Jun. 2022 was €38.19 Mil.

Advanced Oncotherapy Total Current Assets Historical Data

The historical data trend for Advanced Oncotherapy's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Total Current Assets Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Current Assets

Get a 7-Day Free Trial

14.16

15.22

26.18

29.10

36.17

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Total Current Assets	Get a 7-Day Free Trial															28.41	29.10	30.73	36.17	38.19

Advanced Oncotherapy Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Advanced Oncotherapy's Total Current Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.425	+	0.005	+	30.395	+	1.34
	=	36.17

Advanced Oncotherapy's Total Current Assets for the quarter that ended in Jun. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.921	+	0.988	+	34.282	+	-0.00099999999999767
	=	38.19

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Advanced Oncotherapy (FRA:R3I1) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Advanced Oncotherapy's Liquidation Value for the quarter that ended in Jun. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.921	-	107.941	+	0.75 * 0.988	+	0.5 * 34.282
=	-87.14

Advanced Oncotherapy Total Current Assets Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (FRA:R3I1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines